What changed in Guardant Health, Inc.'s latest annual report
In the year ended 31 Dec 2025, Guardant Health, Inc.'s revenue rose 32.9% to USD 982.02m, from USD 739.02m; total assets rose 35.5% to USD 2.01bn, from USD 1.49bn; long-term debt rose 31.6% to USD 1.50bn, from USD 1.14bn.
Year ended 31 Dec 2025. Source: 10-K filed 19 Feb 2026, read it on SEC EDGAR.
USD 739.02m to USD 982.02m
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 739.02m | 982.02m | Up 32.9% |
| Net income | -436.37m | -416.28m | Not comparable |
| Total assets | 1.49bn | 2.01bn | Up 35.5% |
| Total liabilities | 1.63bn | 2.11bn | Up 30% |
| Long-term debt | 1.14bn | 1.50bn | Up 31.6% |
| Cash and cash equivalents | 525.54m | 378.20m | Down 28% |
| Shareholders' equity | -139.65m | -99.31m | Not comparable |
Questions people ask
Did Guardant Health, Inc.'s revenue grow last year?
Revenue grew 32.9%, from USD 739.02m to USD 982.02m in the year ended 31 Dec 2025.
Is Guardant Health, Inc. profitable?
Not in its latest year: it reported a net loss of USD 416.28m in the year ended 31 Dec 2025. The year before: a net loss of USD 436.37m.
How much cash and debt does Guardant Health, Inc. have?
At its latest year end (31 Dec 2025), Guardant Health, Inc. reported cash and cash equivalents of USD 378.20m and long-term debt of USD 1.50bn.
Where do these numbers come from?
From Guardant Health, Inc.'s own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Guardant Health, Inc.?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Services-Medical Laboratories companies
- Natera, Inc.Total liabilities up 47.4%
- Labcorp Holdings Inc.Cash and cash equivalents down 65%
- Quest Diagnostics IncCash and cash equivalents down 23.5%